AstraZeneca plc vs Prospect Capital Corporation — how do they compare? AstraZeneca plc trades at $157.96 (market cap $248.14B), while Prospect Capital Corporation trades at $2.27 (market cap $1.14B). The key difference: AstraZeneca plc is far larger — about 217.7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.93%). Which is the better fit depends on your goals.
| AZN | PSEC | |
|---|---|---|
Market Cap | $248.14B | $1.14B |
Sector | Health | Financials |
52-Week High | $209.48 | $3.05 |
52-Week Low | $147.06 | $2.11 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | 21.93% |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →